晚期糖基化终末产物受体（RAGE）及其多态性变体作为非小细胞肺癌的预测性诊断和预后标志物：一种观点。
Receptor for Advanced Glycation End Products (RAGE) and Its Polymorphic Variants as Predictive Diagnostic and Prognostic Markers of NSCLCs: a Perspective.
作者信息
Mukherjee Tapan K, Malik Parth, Hoidal John R
机构信息
Division of Respiratory, Critical Care and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA.
Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
出版信息
Curr Oncol Rep. 2021 Jan 5;23(1):12. doi: 10.1007/s11912-020-00992-x.
PURPOSE OF REVIEW
Non-small cell lung cancers (NSCLCs) account for ~ 85% of all lung cancers, and 5-year survival in Europe and the USA is ~ 13-17%. In this review, we focus on the significance of Receptor for Advanced Glycation End products (RAGE) as a diagnostic or post-therapeutic prognostic marker for various forms of NSCLCs.
RECENT FINDINGS
The lungs have the highest levels of basal RAGE expression in mammals. The physiologic RAGE in lungs may be involved in adhesion and spreading of AT-1 cells and maintenance of pulmonary homeostasis. However, high level expression of RAGE complicates various diseases including acute lung injury. In NSCLCs, while a number of studies report decreased RAGE expression, inferring a protective role, others suggest that RAGE expression may contribute to NSCLC pathogenesis. Genetic polymorphisms of RAGE are reportedly associated with NSCLC development and complications. RAGE and its polymorphic variants may be useful diagnostic or post-therapeutic prognostic markers of NSCLCs.
综述目的
非小细胞肺癌（NSCLC）约占所有肺癌的85%，在欧洲和美国其5年生存率约为13% - 17%。在本综述中，我们聚焦于晚期糖基化终末产物受体（RAGE）作为各种形式NSCLC的诊断或治疗后预后标志物的意义。
最新发现
肺是哺乳动物中基础RAGE表达水平最高的器官。肺中的生理性RAGE可能参与AT - 1细胞的黏附和扩散以及肺稳态的维持。然而，RAGE的高水平表达会使包括急性肺损伤在内的多种疾病复杂化。在NSCLC中，虽然一些研究报告RAGE表达降低，推断其具有保护作用，但其他研究表明RAGE表达可能促成NSCLC的发病机制。据报道，RAGE的基因多态性与NSCLC的发生发展及并发症相关。RAGE及其多态性变体可能是NSCLC有用的诊断或治疗后预后标志物。
Zotero 插件